NCT07173478

A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Vehicle-controlled, Parallel-group Comparison Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis (Phase 3 Trial)

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 156 (estimated)
• Sponsor: Otsuka Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 15 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

To investigate the superiority of 1% OPA-15406 foam to the vehicle in adult patients with atopic dermatitis (AD).

Conditions

• Atopic Dermatitis (AD)

Interventions

Type	Name	Description
DRUG	OPA-15406	1% foam, topical, twice daily, for 4 weeks
DRUG	Vehicle	vehicle, topical, twice daily, for 4 weeks

Timeline

• Start date: 2025-10-01
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2025-09-15
• Last updated: 2025-09-15

Locations

1 site across 1 country: Japan